Products
-
- 3D BBB Models
- Organ-on-a-Chip BBB ModelsTranswell Models3D BBB Models Culture Substrate
- 3D HydrogelsCollagensCell Lines for BBB Modeling
- Immortalized Cells for BBB ModelingPrimary Cells for BBB ModelingStem Cells for BBB ModelingProteins & Peptides for Stroke ResearchOnline Inquiry
CCR2 covalent NAM (AC137)
Cat.#: ASSD-137
Specifications
Description Chemokine CCR2 covalent negative allosteric modulator (NAM) binds intracellularly and forms a covalent bond with one of three proximal cysteine residues of CCR2. Apparent pKi values at CCR2 are 8.7 and 9.2 (after 4h), where a Ki shift indicates a covalent mode of action. Size 50 μg Chemical Name 2-[[4-[4-Chloro-2-[[4-chloro-3-(trifluoromethyl)phenyl]sulfonylamino]phenoxy]benzoyl]amino]ethyl thiocyanate Molecule Weight 590.4 Molecular formula C23H16Cl2F3N3O4S2 PubChem identifier 162666730 Purity >95% Solubility Soluble in DMSO Storage Store at -20° C Shipping Shipped at 4°C Citation Guidance If you use our product in a scientific publication, please cite it as "Ace Therapeutics Cat.#". Click here to submit your paper's PubMed ID (PMID) to receive rewards. Related Products
Cat.# Name Size Price ASSD-223 Antifade Fluorescence Mounting Medium (aqueous) (AC223) 10 mL inquiry ASSD-206 Eosine-5-isothiocyanate (AC206) 50 mg inquiry ASSD-216 K 114 (AC216) 10 mg, 50 mg inquiry ASSD-218 6-Carboxy-2′,7′-dichlorofluorescein-3′,6′-diacetatesuccinimidyl Ester (AC218) 25 mg inquiry ASSD-127 Fluorescent H3 antagonist [clobenpropit] (AC127) 50 μg inquiry ASSD-224 Antifade Fluorescence Mounting Medium with DAPI (aqueous) (AC224) 10 mL inquiry ASSD-146 Pyronin Y (AC146) 1 g, 5g inquiry ASSD-213 Fluorescein 6-Maleimide (AC213) 25 mg, 250 mg inquiry ASSD-139 Adenosine A1AR Affinity-Based Probe (AfBP) (AC139) 50 μg inquiry ASSD-155 Bromophenol blue (AC155) 5g inquiry All of our products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.
Quick Links0Inquiry Basket